The RX Index Editorial Team · Published May 17, 2026 · Last verified May 17, 2026
A pricing intelligence and comparison resource for GLP-1 telehealth providers.
Published:
Best GLP-1 on Express Scripts Formulary (2026): Verified Coverage Guide
Documents checked: Express Scripts 2026 National Preferred Formulary (PRMT22157-26, 04/01/2026), 2026 NPF Exclusions (EXCL-NPF-26, 04/01/2026), FDA labels, Evernorth releases, Ro and LillyDirect pricing pages. Affiliate disclosure →
The best GLP-1 on Express Scripts formulary documents in 2026 for weight loss is Zepbound Pen — if your specific plan covers obesity medications. Zepbound delivered roughly 22.5% average weight loss at 72 weeks in clinical trials, the highest of any GLP-1 on the formulary, and Express Scripts names Zepbound Pens as a preferred alternative to excluded Zepbound Vials. If your plan prefers semaglutide or you want a pill, Wegovy Injection or Wegovy Tablets are on the 2026 list too.
There's one catch worth knowing before you go any further — and it's the catch that wastes most people's time. Keep reading.
Quick verdict — what to ask your doctor for
| If you want… | Ask about… |
|---|---|
| Maximum weight loss (injection) | Zepbound Pen |
| Semaglutide / heart-disease pathway | Wegovy Injection (2.4 mg) |
| FDA-approved weight-loss pill | Wegovy Tablets |
| Type 2 diabetes | Ozempic, Mounjaro, Rybelsus, or Trulicity |
| Cash-pay oral backup | Foundayo (not on the NPF yet — available cash-pay) |
| Excluded format you should switch off of | Zepbound Vials → switch to Zepbound Pen |
Shortcut if you'd rather skip the phone-tree headache
Submit your insurance details to Ro's free GLP-1 Insurance Coverage Checker. Ro says it contacts your insurer and sends a personalized report showing coverage status, estimated costs, and whether prior authorization may be needed. If you do need a prior auth, Ro's Insurance Concierge can submit it for you.
Run a Free Express Scripts Coverage Check on Ro →The Catch Nobody Tells You: "On the Formulary" Is Not the Same as "Your Plan Covers It"
The most important thing to understand before you ask your doctor for anything
Express Scripts publishes one big drug list called the National Preferred Formulary (the NPF). Your employer then picks and chooses from that list when they design their plan. They can carve out whole categories — like weight-loss meds — even if the drug is sitting right there on the NPF.
Express Scripts says it plainly in their own formulary document: the list "is not all-inclusive and does not guarantee coverage." Translation: a drug being listed means it's available through Express Scripts, not that your plan pays for it.
We'll show you how to check your specific plan in under five minutes further down. For now, here's the verified 2026 picture.
What Is the Best GLP-1 on Express Scripts Formulary in 2026?
Answer capsule:
For weight loss, the strongest first ask on the 2026 Express Scripts National Preferred Formulary is Zepbound Pen — highest average weight loss (~22.5%) and named as a preferred alternative to excluded Zepbound Vials. If your plan prefers semaglutide or you need a pill, Wegovy Injection or Wegovy Tablets are the better path. For Type 2 diabetes, Ozempic and Mounjaro are both on the list with plan-level PA requirements.
We pulled the official 2026 National Preferred Formulary PDF (document PRMT22157-26, effective January 1 – December 31, 2026) and the matching National Preferred Formulary Exclusions document (EXCL-NPF-26, dated April 1, 2026) straight from express-scripts.com. Here's what's on the list.
The 2026 Express Scripts GLP-1 Coverage Matrix
| Medication / Format | On the 2026 NPF? | FDA-approved use | Avg. weight loss |
|---|---|---|---|
| Zepbound Pen (tirzepatide injection) | ✅ Listed; named as preferred alternative to excluded Zepbound Vials | Chronic weight management; moderate-to-severe obstructive sleep apnea in obesity | ~22.5% |
| Zepbound KwikPen | Not separately named in 2026 NPF — Ro and LillyDirect frame KwikPen as a cash-pay option. Verify at plan level. | Same FDA labeling as Zepbound Pen | Same as Zepbound Pen |
| Zepbound Vials ⚠ | ❌ Excluded. Preferred alternatives: liraglutide, Wegovy Injection, Wegovy Tablets, Zepbound Pens | n/a | n/a |
| Wegovy Pen (semaglutide 2.4 mg injection) | ✅ Listed | Chronic weight management; cardiovascular risk reduction (known heart disease + overweight/obesity); noncirrhotic MASH with F2–F3 fibrosis | ~15% |
| Wegovy HD (semaglutide 7.2 mg, FDA-approved March 19, 2026) | NPF lists "WEGOVY PENS" without separately naming HD — verify HD specifically at plan level | Chronic weight management for adults needing higher dose after tolerating 2.4 mg | ~20.7% |
| Wegovy Tablets (oral semaglutide, FDA-approved December 2025) | ✅ Listed; also named as preferred alternative to excluded Zepbound Vials | Chronic weight management (requires morning fasting protocol) | ~16.6% |
| Liraglutide injection (generic Saxenda) | ✅ Listed | Chronic weight management (daily injection) | ~5–8% |
| Saxenda (brand) | ❌ Not listed — generic liraglutide is covered instead | n/a | n/a |
| Ozempic (semaglutide injection) | ✅ Listed | Type 2 diabetes; cardiovascular risk reduction in T2D | Diabetes-lane — not the weight-loss path |
| Ozempic Tablets (oral semaglutide for T2D, FDA-approved Feb 2026) | Not separately verified on 2026 NPF — verify at plan level | Type 2 diabetes (administration restrictions apply) | Diabetes-lane |
| Mounjaro (tirzepatide injection) | ✅ Listed | Type 2 diabetes | Diabetes-lane — Zepbound is the weight-loss tirzepatide brand |
| Rybelsus (oral semaglutide) | ✅ Listed | Type 2 diabetes (administration restrictions apply) | Diabetes-lane |
| Trulicity (dulaglutide injection) | ✅ Listed | Type 2 diabetes | Diabetes-lane |
| Foundayo (orforglipron, FDA-approved April 1, 2026) | ❌ Not yet on 2026 NPF as of May 2026 — coverage forming plan by plan | Chronic weight management; first GLP-1 pill with no food or water restrictions | ~12.4% at highest dose |
Sources: 2026 Express Scripts National Preferred Formulary (PRMT22157-26); 2026 NPF Exclusions (EXCL-NPF-26, April 1, 2026); FDA prescribing information; Eli Lilly investor relations (April 1, 2026 Foundayo approval); Novo Nordisk press release (March 19, 2026 Wegovy HD approval); Drugs.com clinical comparison (April 2026); New England Journal of Medicine trial data.
The fast verdict — what to actually ask your doctor for
- ●For maximum weight loss (if covered): Zepbound Pen
- ●If your plan prefers semaglutide: Wegovy Injection or (if you need a higher dose) Wegovy HD
- ●If you want a pill instead of a shot: Wegovy Tablets (the only weight-loss GLP-1 pill currently on the NPF)
- ●For Type 2 diabetes: Ozempic or Mounjaro, based on your clinician's judgment
- ●If you've been on Zepbound Vials: Switch the conversation to Zepbound Pen (same medication, different device)
- ●Lowest-cost weight-loss option on the formulary: Generic liraglutide injection (daily, lower efficacy)
- ●If you want the new oral pill not yet on the formulary: Foundayo, available cash-pay through LillyDirect or Ro until your plan adds it
Submit your insurance info; Ro contacts your insurer and sends a personalized coverage report. Free, no membership needed to get the report.
What's the Difference Between Zepbound Pen, KwikPen, and Vials on Express Scripts?
Answer capsule:
Zepbound Pen is on the 2026 Express Scripts National Preferred Formulary and is named as a preferred alternative to the excluded Zepbound Vials. Zepbound KwikPen is not separately named on the 2026 NPF document we checked. Zepbound Vials are explicitly excluded from the 2026 NPF.
| Format | What it is | 2026 Express Scripts status |
|---|---|---|
| Zepbound Pen | Pre-filled single-dose pen, the original Zepbound injection device | ✅ On the 2026 NPF; named as preferred alternative to excluded vials |
| Zepbound KwikPen | Multi-dose pen device with multiple injections per pen | Not separately verified on 2026 NPF — Ro and LillyDirect frame KwikPen as a cash-pay route. Verify at plan level before assuming covered. |
| Zepbound Vials ❌ | Single-dose vial format (lower-cost manufacturer self-pay channel) | ❌ Excluded from the 2026 NPF — switch to Zepbound Pen if clinically appropriate |
What this means in plain English
If your doctor writes you a prescription for "Zepbound," your pharmacy might fill it with the Pen, the KwikPen, or the vial depending on what's in stock and how the prescription is written. For Express Scripts coverage, you specifically want Zepbound Pen spelled out. If your prior auth approval comes back for "Zepbound Pen" and the pharmacy tries to substitute, ask them to dispense exactly what the approval names.
So… Is Zepbound or Wegovy the Better First Ask?
Answer capsule:
Ask about Zepbound Pen first if your plan covers obesity medications and your doctor agrees — it has the highest average weight loss (~22.5%) on the formulary. Ask about Wegovy Injection or Wegovy Tablets first if your plan prefers semaglutide, you have established heart disease, you want a pill, or you have noncirrhotic MASH with moderate-to-advanced fibrosis.
Both are on the formulary. Both work. They just hit different doors on the way through prior authorization.
Pick Zepbound Pen if…
- ✓You want the strongest weight-loss outcome on the formulary
- ✓Your plan portal shows Zepbound Pen as covered or only requiring prior auth (not 'excluded')
- ✓You also have moderate-to-severe obstructive sleep apnea — Zepbound has a separate FDA approval for OSA in adults with obesity, which can open a different coverage door when straight obesity coverage is being denied
- ✓You were previously on Zepbound Vials and got cut off — Pen is the preferred alternative on the same formulary
Pick Wegovy Injection (or Wegovy Tablets) if…
- ✓Your plan prefers semaglutide (some do — Cigna/Evernorth has a deeper Novo Nordisk relationship than CVS Caremark)
- ✓You have established heart disease — Wegovy 2.4 mg is FDA-approved to reduce the risk of major cardiovascular events in adults with overweight/obesity and known heart disease
- ✓You have noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) — Wegovy injection 2.4 mg received that FDA approval in 2025
- ✓You want a pill — Wegovy Tablets are the only weight-loss GLP-1 pill on the 2026 NPF
- ✓You need a higher dose than 2.4 mg — Wegovy HD (7.2 mg, approved March 19, 2026)
The honest tradeoff (the part nobody else will tell you)
Zepbound is the strongest medication. That doesn't mean it's the easiest to get covered.
If your employer plan has a tighter relationship with Novo Nordisk (Wegovy's maker) than with Eli Lilly (Zepbound's maker), you may breeze through a Wegovy prior auth and get stuck fighting on Zepbound. That pattern shows up often enough that we recommend asking your doctor's office which one they've been getting approved more easily for Express Scripts patients lately. That's usually the right first ask.
If both are equally available on your specific plan, Zepbound's efficacy advantage is meaningful — about 5 percentage points more average weight loss. Worth the conversation.
The Evernorth $200/Month Cap: The Most Under-Known Benefit on Express Scripts
Answer capsule:
In May 2025, Evernorth (Express Scripts' parent at Cigna) launched a benefit option that caps your out-of-pocket cost for Wegovy and Zepbound at $200/month for participating employer plans — and that $200 counts toward your deductible. The catch: your employer has to specifically opt in. About 9 million Americans were enrolled in Evernorth's broader GLP-1 program (EncircleRx) as of early 2025, but the $200 cap is a separate, newer benefit option.
$200/mo
Maximum out-of-pocket cap for Wegovy or Zepbound
Counts
Toward your annual deductible, not just the cap
$3,600
Potential annual savings vs. manufacturer self-pay programs
Faster
Streamlined prior authorization process per Evernorth
9M+
Americans enrolled in Evernorth's broader EncircleRx GLP-1 program
Opt-in
Your employer must specifically choose to add this benefit
How to find out if your employer enrolled
Call or email HR with this exact question:
If they say yes, your cost is fixed at $200/month for as long as you stay on the medication. If they say no, ask if there's an open-enrollment window where they'd consider adding it. A pointed employee request from a handful of people can move the needle at smaller and mid-sized employers.
What if your employer hasn't opted in?
Manufacturer savings programs can layer with insurance — verify current terms on the day you fill, because they change:
Wegovy Savings Program
Eligible commercially insured patients may pay reduced copays; check current terms at wegovy.com
Zepbound Savings Card
Dose-tiered savings for commercially insured patients; check current terms at zepbound.lilly.com
NovoCare Pharmacy
Direct-from-manufacturer cash-pay channel for Wegovy; verify current terms at novocare.com
LillyDirect
Direct from Eli Lilly — Zepbound Vials, KwikPens, and Foundayo at dose-tiered cash-pay pricing
How to Verify Your Specific Express Scripts Coverage in 5 Minutes (Free)
Answer capsule:
Log into express-scripts.com or the Express Scripts app, use the drug-pricing tool with your plan selected, and check each GLP-1 for tier, prior authorization flag, and step therapy flag. If the portal is unclear, call the number on the back of your insurance card and use the 4-question script below.
The 10-minute coverage checklist
- Log into your Express Scripts member account (express-scripts.com or the mobile app)
- Open the drug-pricing or 'price a medication' tool
- Search Zepbound Pen
- Search Wegovy Injection or Wegovy Pen
- Search Wegovy Tablets
- Search Zepbound Vials — you should see 'not covered' or 'excluded,' confirming your plan follows the NPF exclusions
- Search Ozempic and Mounjaro only if Type 2 diabetes is part of the picture
- Write down or screenshot: tier, copay estimate, prior-auth flag, step-therapy flag, quantity limits
- Search Zepbound KwikPen if your prescriber wants KwikPen specifically — confirm at the plan level rather than assuming
- Bring those screenshots to your doctor's appointment
The 4-question phone script (works on any Express Scripts plan)
Call the number on the back of your card. When you reach a person, say:
"Hi — I'm calling to check coverage for a specific medication. My member ID is [number]. I have four questions."
1. "Is [drug name and exact format — e.g., Zepbound Pen] on my plan's formulary, and what tier is it on?"
2. "Does my plan require prior authorization for this drug? If yes, what are the specific written criteria?" (Get them to say the BMI requirement, comorbidity requirement, and any step therapy out loud.)
3. "Is my plan participating in the Evernorth $200/month GLP-1 cap for Wegovy and Zepbound?"
4. "If [drug] gets denied, what's the next preferred alternative on my plan, and would it require a separate prior authorization?"
Write down the rep's name and the call reference number. That's your paper trail if anything goes sideways later.
Skip the phone tree
Ro contacts your insurer and sends a personalized report showing coverage status, estimated costs, and whether prior authorization may be needed.
Express Scripts GLP-1 Prior Authorization: What You'll Actually Need
Answer capsule:
Many Express Scripts plans require prior authorization for GLP-1s, especially for weight-loss indications, but the exact PA rule is plan-specific. Common obesity-medication PA criteria include BMI documentation, the qualifying indication, comorbidity documentation when relevant, prior treatment history, and no overlapping GLP-1 use.
This is where most denials happen — not because the drug isn't covered, but because something on the prior auth form was missing or wrong.
What your doctor's office will typically need to submit
BMI documented from a recent in-clinic visit
Self-reported BMI doesn't count. Plans typically want a number from a chart note, ideally within the last 6 months. The FDA-approved obesity indication is BMI ≥30, or BMI ≥27 if you also have a weight-related condition.
Comorbidity documentation if your BMI is 27–29
The conditions most commonly accepted: Type 2 diabetes, hypertension, high cholesterol (dyslipidemia), obstructive sleep apnea, established heart disease. The ICD-10 code goes on the form. This is what gets BMI-27 patients approved.
Lifestyle modification history
Many plans want documented effort — dietary counseling, structured exercise, a weight-management program, or visits with a registered dietitian. Your doctor's chart needs to show it.
No concurrent GLP-1
You can't be on Ozempic while requesting Wegovy. If you're switching, your previous prescription needs to be stopped first.
Renewal readiness
Many plans require you to show meaningful weight loss at the 3-month and 6-month mark to keep coverage going. Schedule those follow-ups now, before you fill the first prescription. People lose coverage at renewal more often than at initial approval, and it's almost always a documentation problem.
Who should ask Ro to handle this for you
This is the strongest case for Ro on this page. Ro's Insurance Concierge team submits the prior authorization, follows up if the plan stalls, files an appeal if you get denied, and surveys alternative medications if your first ask doesn't land. They work Express Scripts plans regularly. If your PCP isn't experienced with GLP-1 prior auths — or if you've already tried and got denied — this is what you're paying for with the Ro Body membership.
Have Ro submit your Express Scripts prior authorization →
Get started for $39, then as low as $74/month with the annual plan paid upfront. Membership covers the clinical visits, the PA submission, and follow-up on appeals. Medication cost is separate, and Ro will show you exactly what to expect before you commit. (Verify current Ro pricing at ro.co before signing up.)
Start Ro Body →Don't want to pay for Ro? That's fair.
Some PCPs are excellent with GLP-1 prior authorizations — especially endocrinologists and obesity-medicine specialists. If you have one already, use them. The Obesity Medicine Association maintains a directory at obesitymedicine.org. Ro becomes the better value when you don't have that relationship already in place.
What Oral GLP-1s Are on the Express Scripts Formulary?
Answer capsule:
The 2026 Express Scripts National Preferred Formulary lists Wegovy Tablets (oral semaglutide for weight loss, FDA-approved December 2025) and Rybelsus (oral semaglutide for Type 2 diabetes). Ozempic Tablets (approved February 2026) and Foundayo (approved April 1, 2026) are not separately verified on the 2026 NPF document we checked — coverage is forming plan by plan.
| Oral GLP-1 | What it's for | 2026 NPF status | Key restriction |
|---|---|---|---|
| Wegovy Tablets | Weight loss | ✅ Listed | Strict morning fasting protocol: empty stomach, no more than 4 oz of water, wait 30 minutes before eating |
| Rybelsus | Type 2 diabetes | ✅ Listed | Same fasting protocol as Wegovy Tablets |
| Ozempic Tablets (approved Feb 2026) | Type 2 diabetes | Not separately verified on 2026 NPF — verify at plan level | Administration restrictions apply |
| Foundayo (orforglipron, approved April 1, 2026) | Weight loss | Not yet on 2026 NPF — coverage forming | No food or water restrictions — take any time of day |
What makes Foundayo different from the other oral options
Foundayo is the first non-peptide, small-molecule oral GLP-1. The big practical difference: no fasting required. Wegovy Tablets and Rybelsus both need you to take them on an empty stomach with no more than 4 oz of water, then wait before eating. Foundayo doesn't — take it whenever.
- Average weight loss in trials: ~12.4% at the highest dose — less than Zepbound (~22.5%) and Wegovy HD (~20.7%), but the convenience matters for people who hate needles or can't manage the fasting protocol.
- Cash-pay through LillyDirect starts at $149/month for the starter dose; higher doses are dose- and offer-dependent, so verify current pricing before committing.
Should you ask for a Foundayo formulary exception?
If your plan covers other GLP-1s and you have a real reason to prefer Foundayo (severe needle phobia, an inability to follow Wegovy Tablets' fasting protocol, or another medical reason), your doctor can submit a formulary exception request to Express Scripts arguing medical necessity. Approval depends on your plan's rules, your documentation, and what preferred alternatives are available. The faster path is self-pay through Ro, which already carries Foundayo. See our Foundayo availability guide for the full breakdown.
What If My Plan Doesn't Cover Weight-Loss Meds at All?
Answer capsule:
If your Express Scripts plan excludes weight-loss medication, you still have three real paths in 2026: (1) qualify under a different FDA-approved indication, (2) pay cash through LillyDirect, NovoCare, or Ro, or (3) request a formulary exception with documented medical necessity. The first path works more often than people realize.
Path 1 — The non-obesity FDA-approved pathway (use this first)
The FDA has approved GLP-1s for conditions other than weight loss, and many employer plans that exclude "obesity meds" still cover those non-obesity indications.
Wegovy injection 2.4 mg
FDA-approved to reduce the risk of major cardiovascular events in adults with established heart disease who are also overweight or obese. If you have a documented cardiac history, your doctor submits the prior auth under this indication — not under obesity. Different criteria. Often less restrictive coverage.
Wegovy injection 2.4 mg (MASH indication)
Also FDA-approved for noncirrhotic MASH with F2–F3 fibrosis (a serious liver condition). Separate indication, separate prior auth, separate coverage logic. Note: this MASH approval is for the 2.4 mg injection specifically, not Wegovy HD or Wegovy Tablets.
Zepbound
FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024). Many plans that exclude obesity drugs do cover sleep apnea treatment.
This is honest medicine, not a loophole. Your doctor still has to truthfully document the qualifying condition. But if you have heart disease, MASH, or sleep apnea — and many people who are looking at GLP-1s do — this can be the entire reason a previously denied request gets approved.
Path 2 — Cash-pay channels worth knowing
LillyDirect
Direct from Eli Lilly. Zepbound Vials and KwikPens at dose-tiered pricing; Foundayo at $149–$349/month depending on dose. Verify current terms at lilly.com/lillydirect.
NovoCare Pharmacy
Direct from Novo Nordisk. Wegovy at cash-pay pricing for uninsured patients or plans that exclude. Verify current terms at novocare.com.
Ro Body
Full FDA-approved menu including Wegovy Pen, Wegovy Tablets, Zepbound KwikPen, Foundayo, and Ozempic, with concierge support whether you're going through insurance or self-pay.
GoodRx
Coupons that sometimes beat the manufacturer cash price, depending on pharmacy and dose.
Path 3 — Formulary exception request
Your doctor submits an exception request to Express Scripts arguing that the standard formulary doesn't meet your medical needs. These work best when you have a documented contraindication to the plan's preferred alternatives, you've already tried and failed on a preferred drug, or your clinician writes a clear letter of medical necessity.
If you're at this stage, you really want Ro's concierge or a specialist who handles these regularly — generic PCPs often don't have the template or the persistence.
We'll map your best GLP-1 path based on your insurance status, state, and goals — no email required.
What We Actually Verified (and What We Didn't)
This is the part most pages won't show you. Here's exactly what we checked, and exactly what we couldn't.
✅ Verified directly from primary sources
- ✓The 2026 Express Scripts National Preferred Formulary document (PRMT22157-26, effective Jan 1 – Dec 31, 2026, dated 04/01/2026) lists Wegovy Pens, Wegovy Tablets, Zepbound Pen, Ozempic, Mounjaro, Rybelsus, Trulicity, and liraglutide injection.
- ✓The 2026 NPF Exclusions document (EXCL-NPF-26, dated 04/01/2026) explicitly excludes Zepbound Vials and names the preferred alternatives as: liraglutide, Wegovy Injection, Wegovy Tablets, and Zepbound Pens.
- ✓The Evernorth $200/month cap launched May 21, 2025.
- ✓Evernorth announced in 2025 that Ozempic and Rybelsus would return to the Patient Assurance Program.
- ✓Wegovy HD (semaglutide 7.2 mg injection) received FDA approval on March 19, 2026.
- ✓Wegovy Tablets (oral semaglutide for weight loss) received FDA approval in December 2025.
- ✓Foundayo (orforglipron) received FDA approval on April 1, 2026.
- ✓Average weight-loss percentages cited come from published FDA-trial data and clinical comparison reporting (Drugs.com, April 2026).
⚠️ We could NOT verify (because it's plan-specific)
- Your specific copay tier
- Your plan's exact prior authorization criteria
- Whether your employer opted into the $200/month Patient Assurance Program
- Whether your plan uses the standard NPF or a customized formulary
- Whether weight-loss drugs are covered under your specific employer plan at all
- Whether Zepbound KwikPen is covered by your specific plan
- Your deductible, out-of-pocket maximum, or coinsurance percentage
🔄 What could change before our next quarterly update
- Foundayo getting added or excluded — re-check the NPF and your plan portal monthly
- Ozempic Tablets showing up explicitly on the NPF
- Mid-year amendments to formulary status
- Expansion of the $200/month cap to additional employer plans
- Changes to Ro, NovoCare, or LillyDirect pricing
- Updates to step-therapy or appeal rules
We re-verify this page every quarter, and immediately when there's an Express Scripts formulary amendment, an FDA approval that adds a GLP-1, or a major pricing change.
How Express Scripts Compares to CVS Caremark and OptumRx for GLP-1s
Answer capsule:
On the default public formulary documents we checked, Express Scripts is more favorable to Zepbound Pen than CVS Caremark's standard commercial template in 2026. Express Scripts keeps both Wegovy and Zepbound Pen on its National Preferred Formulary and offers the $200/month cap option to employers. CVS Caremark made Wegovy and Saxenda its preferred GLP-1s starting July 1, 2025, and excluded Zepbound from its standard commercial template.
| PBM | Wegovy | Zepbound Pen | Zepbound Vials | Notable 2026 difference |
|---|---|---|---|---|
| Express Scripts (Cigna/Evernorth) | ✅ Injection + Tablets covered | ✅ Listed | ❌ Excluded; preferred alternative is Pen | $200/mo cap option available to employers; both major brands on NPF |
| CVS Caremark | ✅ Preferred | ❌ Excluded from standard commercial template July 2025 | ❌ | Wegovy and Saxenda are CVS's preferred GLP-1s; Zepbound members on the standard template had to switch or pay cash |
| OptumRx | Plan-dependent | Plan-dependent | Plan-dependent | More variation by employer; less standardized than the other two |
Methodology note: This comparison reflects the default public formulary documents and templates each PBM has published for 2026. Your actual employer plan can override these defaults — always verify in your own plan portal.
If you have a choice at open enrollment between plans on different PBMs and you want Zepbound specifically, the Express Scripts public template is more favorable than CVS Caremark's in 2026. If you're on Wegovy, all three PBMs cover it on most templates.
Side Effects and Safety: The Part You Should Not Skim
GLP-1 medications work, and they're not for everyone. Here's what you need to know before talking to your prescriber.
Common side effects
Per the FDA-approved prescribing information: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, and reduced appetite. Most people experience these primarily in the first few weeks while doses titrate up.
Boxed warning (FDA's most serious warning)
Applies to Wegovy, Zepbound, Foundayo, Ozempic, Rybelsus, Mounjaro, and other GLP-1 or GIP/GLP-1 medications. Each carries thyroid C-cell tumor warnings based on rodent studies, and each is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
Other serious risks to discuss with your doctor
Pancreatitis, gallbladder problems, hypoglycemia (especially when combined with other diabetes medications), acute kidney injury, serious allergic reactions, and (for some products) suicidal thoughts or behavior have been reported.
This is not the complete list of side effects or safety information. Specific risks, dosing instructions, and contraindications vary by medication and formulation. Read the full prescribing information your pharmacy provides for your specific drug, and talk to your prescriber about your medical history. A GLP-1 may not be appropriate for you, and only a clinician who knows your full picture can make that call.
Express Scripts GLP-1 Decision Tree
If you're still figuring out where to start, here's the shortest path from where you are to the right next step.
Are you treating weight loss, Type 2 diabetes, or something else?
For weight loss: does your plan cover obesity medications?
Do you prefer a pill or a shot?
Has your plan flagged prior authorization?
Frequently Asked Questions
- What is the best GLP-1 on Express Scripts formulary in 2026?
- For weight loss, Zepbound Pen is the strongest first ask — it has the highest average weight loss (~22.5%) of any GLP-1 on the formulary and is named as a preferred alternative to the excluded Zepbound Vials. If your plan prefers semaglutide, you need Wegovy's heart-disease or MASH indication, or you want a pill, Wegovy Injection or Wegovy Tablets is the better path. For Type 2 diabetes, Ozempic and Mounjaro are both listed; the right choice depends on your clinician's judgment about your diabetes profile.
- Is Wegovy covered by Express Scripts in 2026?
- Wegovy Pens and Wegovy Tablets are both on the 2026 Express Scripts National Preferred Formulary. Whether your specific plan covers them depends on whether your employer opted into weight-loss medication coverage and whether prior authorization criteria are met. Wegovy HD (the higher-dose 7.2 mg version approved March 2026) is treated under the broader Wegovy Pens category, but verify HD specifically at the plan level.
- Is Zepbound covered by Express Scripts in 2026?
- Zepbound Pen is on the 2026 Express Scripts National Preferred Formulary. Zepbound Vials are explicitly excluded — the 2026 Exclusions document names liraglutide, Wegovy Injection, Wegovy Tablets, and Zepbound Pens as preferred alternatives. Zepbound KwikPen is not separately named on the NPF document we checked; verify KwikPen at the plan level if your prescriber wants you specifically on KwikPen.
- Does Express Scripts cover Foundayo (orforglipron)?
- Not yet, as of May 2026. Foundayo was FDA-approved on April 1, 2026 — the same day the 2026 Express Scripts National Preferred Formulary document was issued. Coverage is forming plan by plan. Immediate options include LillyDirect self-pay starting at $149/month for the starter dose, the Foundayo Savings Card if your plan does add the medication, or a formulary exception request through your doctor.
- What is the Evernorth $200/month GLP-1 cap?
- It's a benefit option Evernorth (Express Scripts' parent at Cigna) introduced in May 2025 that caps your monthly out-of-pocket cost for Wegovy and Zepbound at $200, with that $200 counting toward your annual deductible. Your employer has to specifically opt in — it's not automatic. Evernorth has since announced that Ozempic and Rybelsus would return to the broader Patient Assurance Program in 2025.
- What BMI do I need to qualify for a GLP-1 through Express Scripts?
- The FDA-approved obesity criteria are BMI ≥30, or BMI ≥27 with at least one weight-related condition like Type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or established heart disease. Many Express Scripts plans follow this standard for prior authorization, but your specific plan's criteria may differ. The BMI has to be documented from a recent clinical visit — self-reported numbers don't count.
- What happens if Express Scripts denies my GLP-1 prior authorization?
- You have several real options. Resubmit if the denial was for missing documentation. Appeal if the denial was a clinical judgment call. Try a different indication — if you have heart disease, sleep apnea, or noncirrhotic MASH, Wegovy injection 2.4 mg or Zepbound has separate FDA-approved uses with different prior auth logic. Or switch to cash-pay through LillyDirect, NovoCare, or Ro while continuing to fight for coverage. Keep the written denial reason, submission date, and any reference numbers — you'll need them for the appeal.
- Is Ozempic covered by Express Scripts for weight loss?
- Ozempic is on the 2026 Express Scripts formulary, but it's covered for Type 2 diabetes, not weight loss. Ozempic is FDA-approved for diabetes — Wegovy is the FDA-approved weight-loss product with the same active ingredient (semaglutide). If your prescriber requests Ozempic for weight loss without a Type 2 diabetes diagnosis, expect denial. Ask about Wegovy instead.
- Is Mounjaro the same as Zepbound for coverage purposes?
- No. Mounjaro and Zepbound both contain tirzepatide, but they're FDA-approved for different uses. Mounjaro is approved for Type 2 diabetes; Zepbound is approved for weight management and obstructive sleep apnea in obesity. Express Scripts covers both, but the prior authorization criteria are different. If you want tirzepatide for weight loss, the right ask is Zepbound — not Mounjaro.
- How long does Express Scripts prior auth take for a GLP-1?
- Ask your plan for its expected timeline. When complete documentation is submitted, many plans respond within a week; incomplete submissions and appeals add time. Keep your submission date, reference number, and any written PA criteria so you can follow up. If you'd rather have someone else manage the timeline for you, Ro's Insurance Concierge handles Express Scripts plans regularly.
- Where can I fill my GLP-1 prescription through Express Scripts?
- You can fill at any in-network retail pharmacy or through home delivery via Evernorth EnGuide Pharmacy, which is staffed by pharmacists trained specifically on GLP-1s. If your plan participates in the $200/month cap program, both retail and home delivery work at the capped price.
- Does my employer have to cover GLP-1s if they're on the Express Scripts NPF?
- No. The National Preferred Formulary is the default Express Scripts builds, but employers can opt out of categories (especially weight-loss medications), customize tiers, apply step therapy, or limit coverage to certain indications. Coverage is ultimately your employer's decision. If your plan excludes obesity meds entirely, the non-obesity FDA-approved indications, cash-pay channels, and formulary exception requests are your real alternatives.
The Bottom Line
The best GLP-1 on Express Scripts formulary in 2026 is Zepbound Pen for weight loss and Mounjaro or Ozempic for Type 2 diabetes — but only if your specific plan covers them. Wegovy Injection, Wegovy HD, and Wegovy Tablets are the strongest semaglutide alternatives, especially if your plan prefers Novo Nordisk's drugs or you have a qualifying heart-disease or MASH indication. Zepbound Vials are explicitly excluded — switch the conversation to Zepbound Pen. Foundayo isn't on the formulary yet but is available cash-pay starting at $149/month for the starter dose.
If your plan excludes weight-loss meds entirely, three paths still work: indication-switching (heart disease, sleep apnea, MASH), cash-pay channels, or a formulary exception request. Don't assume "not covered" means "no path forward."
$39 for the first month, then as low as $74/month annual plan. Verify current pricing at ro.co before signing up.
About this page: Researched and written by The RX Index editorial team. We pulled the 2026 Express Scripts National Preferred Formulary PDF and the 2026 NPF Exclusions document directly from express-scripts.com and verified every GLP-1's listing or exclusion against those primary sources. We cross-checked the Evernorth Patient Assurance Program details against Evernorth and Cigna corporate communications, and verified FDA-approval dates and clinical trial data against the FDA, Drugs.com, and the New England Journal of Medicine.
Affiliate disclosure: When you click through to Ro or other providers linked on this page, we may earn a commission if you start a paid membership. This never changes our recommendation logic. Our editorial verdicts are determined by clinical fit, coverage logic, and verified pricing, not affiliate payouts. Read our full affiliate disclosure →
Medical disclaimer: This is an informational coverage guide, not medical advice. Before starting any medication, talk to a clinician who knows your full medical history.
Last verified: May 17, 2026. We re-check this page quarterly and immediately when there's an Express Scripts formulary amendment, an FDA approval that adds a GLP-1, or a major pricing change.
Sources
- –2026 Express Scripts National Preferred Formulary (PRMT22157-26, effective Jan 1 – Dec 31, 2026)
- –2026 Express Scripts National Preferred Formulary Exclusions (EXCL-NPF-26, dated April 1, 2026)
- –Evernorth press releases (May 2025 launch of Patient Assurance Program GLP-1 expansion; 2025 announcement of Ozempic and Rybelsus return)
- –Eli Lilly investor relations (April 1, 2026 Foundayo FDA approval)
- –Novo Nordisk press release (March 19, 2026 Wegovy HD FDA approval)
- –FDA prescribing information for Zepbound, Wegovy, Foundayo, Ozempic, Mounjaro, Rybelsus, Trulicity
- –New England Journal of Medicine trial data (Jastreboff et al., Frias et al., Wharton et al., Lincoff et al.)
- –Drugs.com clinical comparison (Anderson, PharmD, April 2026)
- –Ro pricing and coverage pages (ro.co)
- –LillyDirect and NovoCare cash-pay channels